Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Seyltx gains option to boost cough pipeline with 8 NeurOp drugs
Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp.
James Waldron
Jun 5, 2025 10:40am
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Jun 5, 2025 4:38am
Vividion secures clinical-stage WRN inhibitor from Roche
Jun 4, 2025 9:21am
Eli Lilly taps Camurus' tech to advance long-acting obesity meds
Jun 3, 2025 5:04pm
BioAge inks option agreement for Chinese biotech's obesity asset
Jun 3, 2025 2:06pm
Transpire licenses PDE4 inhibitor for lung disease
Jun 3, 2025 9:45am
